PharmPK Discussion - Biomarker roundtables at AAPS in Atlanta

• On 10 Nov 2008 at 10:32:36, "Tata, Prasad N" (Prasad.Tata.at.Covidien.com) sent the message
  

  
  Identification and Validation of Biomarkers
  
  Dear All:
  
  I am moderating  a round table discussion on  "Identification and
  Validation of Biomarkers" on November 19, 2008 Wednesday 9.00 am
  -11.00 am during  the upcoming AAPS  annual meeting Biomarkers
  identification for a specific disease and proper validation of their
  quantitative methodology plays a role in setting up biomarker program.
  We evaluate various strategies for a robust biomarkers program.  I am
  requesting you to post any questions you may have so that we can try
  to get answers for your question during this round table and I will
  post discussion results in these fora.
  
  Please send your questions to prasad.tata.aaa.covidien.com
  
  Thanks,.
  
  Prasad
  Prasad NV Tata, MS, Ph.D., FCP
  Manager-Pharmacokinetics
  Mallinckrodt, Inc.
  675 McDonnell Blvd.
  Saint Louis, MO 63134
  e-mail: prasad.tata.-a-.covidien.com
  
  --
  
  Development and Maintaining a Biomarker Monitoring Program - Round
  table discussion during AAPS annual meeting.
  
  Dear All:
  
  I am moderating  a round table discussion on  "Development and
  Maintaining a Biomarker Monitoring Program" on November 19, 2008
  Wednesday 1.00 am -3..00 pm during  the upcoming AAPS  annual meeting
  in Atlanta during this round table we discuss  Biomarkers have
  attained a pivotal place in drug development. There needs to be a
  clear understanding of rational biomarker identification and validated
  programs in place for meaningful drug development process. Properly
  selected biomarkers offer efficient drug development process. In this
  session we discuss how to run a meaningful biomarker program. I am
  requesting you to post any questions you may have so that we can try
  to get answers for your question during this round table and I will
  post discussion results in these fora.
  
  Please send your questions to prasad.tata.at.covidien.com
  
  Thanks,.
  Prasad
  Prasad NV Tata, MS, Ph.D., FCP
  Manager-Pharmacokinetics
  Mallinckrodt, Inc.
  675 McDonnell Blvd.
  Saint Louis, MO 63134
  e-mail: prasad.tata.aaa.covidien.com
  
  

  Back to the Top

• On 10 Nov 2008 at 16:57:17, "Michael Karol" (MKarol.aaa.syntapharma.com) sent the message
  

  
  The following message was posted to: PharmPK
  
  Dear Prasad
  
      I think it would be very interesting to hear a compare and
  contrast discussion regarding how identification and validation
  efforts differ for drug development paths where the drug candidate is
  not yet approved (ie: developing for the first indication) versus an
  approved drug going for additional indications.
  
  Regards,
  Michael
  --
  Michael D. Karol, Ph.D.
  Senior Director, Clinical Pharmacology
  Synta Pharmaceuticals Corp.
  45 Hartwell Ave
  Lexington, MA 02421
  
  MKarol.-at-.SyntaPharma.Com
  
  

  Back to the Top

Copyright 1995-2011 David W. A. Bourne (david@boomer.org)